Kelly Brady, Executive Vice President and Chief Operating Officer of Seres Therapeutics, Inc. (NASDAQ:MCRB), filed a Form 4 on November 17, 2026, disclosing restricted stock unit vesting and a subsequent share sale that occurred on November 15 and 16, 2026.

Key Highlights

  • RSU conversions: 89 restricted stock units from one grant and 92 restricted stock units from a second grant converted to common stock on November 15, 2026, for a combined total of 181 shares acquired.
  • Share sale: 85 shares of common stock were sold on November 16, 2026, at $1.38 per share, pursuant to a Rule 10b5-1 plan.
  • 10b5-1 plan: According to the filing, the plan was adopted by Brady on November 26, 2025.
  • Remaining beneficial ownership: Following all reported transactions, Brady directly held 8,775 shares of common stock, 90 restricted stock units from the first grant, and 456 restricted stock units from the second grant.
  • Signing authority: The form was signed by Thomas J. DesRosier as attorney-in-fact for Kelly M. Brady.

Brady's RSU Vesting and Sale Activity at Seres Therapeutics

According to the filing, Kelly Brady, who serves as EVP and Chief Operating Officer of Seres Therapeutics, a biotherapeutics company based in Cambridge, Massachusetts, reported two separate restricted stock unit conversions on November 15, 2026. The first conversion involved 89 restricted stock units, each representing a contingent right to receive one share of common stock, with an exercise price of $0. The second conversion covered 92 restricted stock units under a separate grant, also at an exercise price of $0. Together, the two conversions resulted in 181 shares of common stock being acquired.

The filing states that the first grant vested as to 25% of the restricted stock units on February 15, 2024, with the remainder vesting in 12 equal quarterly installments thereafter. The second grant vested as to 25% on February 15, 2025, with the remainder similarly vesting over 12 equal quarterly installments. Neither grant carries an expiration date, according to the filing. Following the November 15 conversions, 90 restricted stock units from the first grant and 456 restricted stock units from the second grant remained outstanding.

On November 16, 2026, Brady sold 85 shares at $1.38 per share. The filing notes that "the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 26, 2025, with the intent to cover taxes in connection with the vesting of the restricted stock units." After this sale, Brady's direct beneficial ownership in common stock stood at 8,775 shares.

What Was Disclosed

This Form 4 covers the vesting of 181 restricted stock units into common stock and a subsequent Rule 10b5-1 plan sale of 85 shares at $1.38 by Brady on November 15 and 16, 2026, leaving Brady with 8,775 common shares and 546 total remaining restricted stock units across two grants.